Kornimate/medical-research-clean huggingface dataset:
positron emission tomography scan and ct scan in planning radiation therapy for patients with stage ii or stage iii non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: imaging procedures, such as positron emission tomography (pet) scan and ct scan, may help doctors plan radiation therapy for patients with non-small cell lung cancer. purpose: this clinical trial is studying how well a combined pet scan and ct scan works compared to a ct scan alone in planning radiation therapy for patients with stage ii or stage iii non-small cell lung cancer.

objectives: primary * determine the impact of positron emission tomography (pet)/ct fusion scan and ct scan alone, by comparing gross tumor volume (gtv) contours and three-dimensional conformal radiotherapy treatment plans using 2 separate data sets (pet/ct fusion scan and ct scan only), in patients with stage ii or iii non-small cell lung cancer who are planning to undergo radiotherapy. * determine the impact of pet on gtv (cm\^3), number of involved nodes, location of involved nodes, and dosimetric measures of normal tissue toxicity (mean lung dose, v20, and mean esophageal dose). secondary * determine the rate of elective nodal failures (nodal failures in regions that are not intentionally irradiated to definitive doses \[i.e., ipsilateral hilum, mediastinum, or ipsilateral supraclavicular fossa\]). outline: this is a multicenter study. patients are stratified according to neoadjuvant chemotherapy (yes vs no). patients undergo a combined positron emission tomography (pet)/ct scan. patients also undergo a ct scan alone. a single three-dimensional conformal radiotherapy (3dcrt) plan is generated from the combined pet/ct scan results. a single 3dcrt plan using the planning target volume is derived from the ct scan only. patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. projected accrual: a total of 48 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed non-small cell lung cancer (nsclc) * stage iia/iib or stage iiia/iiib disease * planning to undergo radiotherapy * local or regional nodal recurrence after surgery allowed * no malignant pleural effusion patient characteristics: * zubrod performance status 0-2 * negative pregnancy test * not pregnant or nursing * fertile patients must use effective contraception prior concurrent therapy: * see disease characteristics * concurrent neoadjuvant and/or concurrent chemotherapy allowed * no concurrent intensity-modulated radiotherapy

Keywords: stage ii non-small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer recurrent non-small cell lung cancer
post-stroke delirium screening

Conditions: Delirium; Ischemic Stroke; Transient Ischemic Attack

Summary: for a long time, delirium was considered a merely temporary dysfunction of the brain. today, it is established that it is a brain disease associated with network dysfunction, neuroinflammation and impaired transmitter homeostasis in a multicausal model. following an episode of delirium, many patients do not return to their prior level of cognitive and functional performance. in particular, failed or delayed diagnosis with consecutive inadequate therapy contribute to the development of long-term cognitive decline that may ultimately lead to long-term care. stroke patients are a particularly common delirium-affected population (10-46% depending on severity). despite the frequency and clinical relevance of delirium in stroke patients, diagnostic characteristics of common screening methods are unknown. similarly, the clinical phenotype and risk factors of patients who develop delirium have not been adequately described. this study primarily aims to evaluate the diagnostic properties of established screening tools for delirium in a prospective cohort of well-characterised patients following ischemic cerebral events (either transient or manifest stroke). secondary outcome criteria include predictors of post-stroke delirium (psd) such as stroke location and size, pre-stroke cognitive functioning, ability to participate in daily routine activities and medical conditions.


Eligibility criteria:
inclusion criteria: * stroke unit admission for a high-risk transient ischemic attack (abcd2 score \>= 6) or stroke within the last 24 hours exclusion criteria: * hemorrhagic stroke

Keywords: stroke delirium screening tool
molecular panel evaluation for diagnosis of infections of the central nervosous system

Conditions: Infections Nervous System

Summary: infections involving the central nervous system (cns), such as meningitis/encephalitis (me), are serious clinical conditions associated with high morbidity and mortality rates, as well as significant long-term consequences. me can be caused by a wide variety of pathogenic agents. clinical symptoms may vary and it has been shown that early identification of the pathogens causing me allows for timely and appropriate treatment, thus reducing permanent neurological damage. the multiparameter panel "qiastat-dx®meningitis/encephalitis" can detect in one hour on a sample of 15 bacterial, viral and fungal pathogens. in the diagnostic routine, real-time pcr takes an average of 3 hours and culture examination 2 days. in addition, compared to other comparable rapid molecular systems, the "qiastat-dx" platform has the ability to generate a cycle-related threshold value (ct) for the targets detected. this value may have a correlation with the viral load and thus provide in a short time not only the result of positivity, but also an indication of the amount of virus present. other commercially available multiparameter molecular tests provide only qualitative data.

the study is on biological samples of cerebrospinal fluid, positive for viruses or bacteria of interest, retrospective, monocentric, non-pharmacological. for each sample included in the study (170 total samples), the molecular/culture test result, provided by the normal diagnostic process at the microbiology unit, is available for comparison with those obtained with the multiparameter panel qiastat-dx® meningitis/encephalitis (me) and qiastat-dx 1.0 analyzer. the aim of the study is: 1. to evaluate the analytical sensitivity of the test by identifying positive samples for bacteria (culture comparison) and positive samples for viruses (qpcr comparison). 2. compare the value of ct obtained with the number of viral copies per ml of cerebrospinal fluid obtained by qpcr.

Eligibility criteria:
inclusion criteria: * 170 samples of csf positive for virus and/or bacteria; * samples stored at -80°c, less than 5 years; * samples with a volume of at least 800μl. exclusion criteria: * samples of a different matrix than csf; * samples stored at room temperature; * samples for which diagnostic test results are not available; * samples with a volume of less than 800μl; * samples already thawed and refrozen.

Keywords: central nervous system infections bacterial infection viral infection meningitis encephalitis
management of signs and symptoms associated with dry eye disease

Conditions: Dry Eye Syndromes

Summary: a prospective randomized, and controlled study to compare the effectiveness of prokera® slim plus standard of care (soc) in the prokera® slim arm to soc alone in the control arm. subjects presenting with moderate ded defined as corneal fluorescein staining score of ≥ 3 points out of 9 will be recruited.


Eligibility criteria:
inclusion criteria: * subjects with moderate dry eye defined as corneal fluorescein staining score of ≥ 3 * age ≥ 18 years * distance best corrected visual acuity better than 20/60 snellen equivalent in each eye * willing to sign a written informed consent to participate * able to follow study instructions, with the intention of completing all required visits exclusion criteria: * presence of persistent corneal epithelial defect or ulcer in either eye * presence of active ocular infection in either eye * presence of ocular inflammation that is not related to keratoconjunctivitis sicca, e.g., allergy, severe blepharitis * presence of other corneal disorder(s) that give rise to reduced corneal sensitivity, such as recurrent herpes keratitis * presence of corneal diseases other than dry eye that can disturb the pre-corneal tear film such as epithelial basement membrane dystrophy (ebmd) * contact lens wear * history of recent ocular surgery/trauma, which could affect corneal sensitivity, e.g., corneal transplantation, lasik * presence of cicatricial ocular surface diseases * a medical or ocular condition, or a personal situation, which in the principal investigator's opinion, is not appropriate for participation in the trial * any scheduled or planned ocular or systemic surgery or procedure during the study * pregnancy and women who are expecting to be pregnant. * current enrolment in another interventional drug or device study or participation in such a study within 30 days of anticipated entry into this study
turkish version of occupational balance-questionnaire (ob-quest)

Conditions: Occupational Balance; Occupational Therapy; Survey; Assessment

Summary: the objective of this study was to translate and culturally adapt the occupational balance questionnaire (ob-quest) and evaluate the psychometric properties of the translated version by validity and reliability testing.

this study consists of two parts; in the first part, the translation and cross-cultural adaptation were undertaken, and in the second part, analyses of psychometric properties of ob-quest turkish were performed. part i: translation and cross-cultural adaptation the developers of the original questionnaire were contacted to seek their permission to translate the ob-quest into turkish and permission was obtained by the researchers via email. the five-stage translation-back translation method proposed by beaton et al were used in the cross-cultural adaptation of the questionnaire (beaton et al., 2000). the first stage included translation procedures, and two therapists translated the questionnaires' english form into turkish. in the second stage, two translations were compared to avoid any discrepancy and converted a single text by the research team. generally, ob-quest has a simple and understandable sentence structure. therefore, it did not require any cultural adaptation, simple arrangement was enough to provide clarity. researchers arranged on the last two items. these items consisting of a single sentence were divided into two as 'example and question', to overcome the complexity of the questions and maintain the integrity of the meaning. after the corrections, researchers had an agreement on the turkish version of ob-quest. in the third stage, the back translation of the final text from turkish to english was made by two native english speakers whose turkish very well. in the fourth step, the researchers compared the original text with the last english form and produced the final version. the final stage covered the pilot study to get understanding items. after the translation process was completed, a pilot study was conducted with a group of 30 people. participants approved the final version was appropriate and understandable. the participants in the pilot study did not include in the sample group. part ii analysis of the psychometric properties of ob-quest

Eligibility criteria:
inclusion criteria: * aged 18-65 years * native speakers of turkish * literate of turkish * healthy * volunteered to participate in the study exclusion criteria: * diagnosed with acute/chronic disease
safety and pharmacokinetics of azelaic acid foam, 15% in papulopustular rosacea

Conditions: Papulopustular Rosacea

Summary: assessment of pharmacokinetics of azelaic acid foam after repeated skin application and in comparison to azelaic acid gel. assessment of safety after repeated skin application.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate papulopustular rosacea * free of any clinically significant disease exclusion criteria: * body weight less than 50 or more than 130 kg * clinically significant disease which could interfere with the study
bevacizumab and cetuximab in combination with folfox6 in patients with metastatic colorectal cancer

Conditions: Colon Cancer

Summary: this trial will evaluate the combination of modified infusional 5-fluorouracil/ leucovorin, oxaliplatin (folfox6), bevacizumab, and cetuximab in patients with metastatic colorectal cancer. folfox6 has proven to be a safe and effective regimen in first line treatment of advanced colorectal cancer. the role of epidermal growth factor (egfr) inhibitors in an earlier treatment setting in combination with optimal chemotherapy regimens is an important emerging question.

all patients received cetuximab: 400 mg/m2 (first cycle only) administered intravenously (iv) on day 1 and 250 mg/m2 iv on day 8 with all subsequent cycles 250 mg/m2 iv on days 1 and 8. day 1 cetuximab was immediately followed by bevacizumab 5 mg/kg iv, oxaliplatin 85 mg/m2 iv, and 5-fluorouracil 400 mg/m2 iv bolus, followed by 2400 mg/m2 administered as a continuous infusion over 46 hours via a pump (outpatient) and leucovorin 350 mg iv (modified folfox6). cycles were 14 days.

Eligibility criteria:
inclusion criteria: to be included in the study, you must meet the following criteria: * metastatic colorectal cancer confirmed by a biopsy sample * 18 years of age or older * evidence of disease progression at time of study entry * at least one prior adjuvant chemotherapy regimen * no prior therapy for metastatic disease * measurable disease * able to perform activities of daily living with minimal assistance * adequate bone marrow, kidney, and liver function * tumor tissue available for assessment of egfr * signed informed consent exclusion criteria: you cannot participate in the study if any of the following apply to you: * treatment with a previous regimen for metastatic disease * prior treatment with any egfr inhibitor or anti-angiogenic agents * brain or nervous system metastases * history of severe thromboembolic event * clinical evidence or history of bleeding or coagulopathy * history of stroke or heart attack within six months * poorly controlled hypertension * non-healing wound, ulcer, or bone fracture * history of abdominal fistula, perforation, or abscess within six months * other uncontrolled or significant disease or medical condition please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have. you can then decide if you wish to participate.

Keywords: colon cancer
transperitoneal vs retroperitoneal laparoscopic or robotic partial nephrectomy

Conditions: Renal Cell Carcinoma

Summary: both laparoscopic partial nephrectomy (lpn) and robotic partial nephrectomy (rpn) can be performed through transperitoneal (tp) or retroperitoneal (rp) approach. rp approach is less utilized than tp approach because of technical difficulties when using rigid laparoscopic instruments in the small space of retroperitoneum cavity. however, with advanced surgical skills and thoughtful patient selection, rp approach may be associated with shorter operative time (ot), less estimated blood loss (ebl), shorter length of hospital stay (los) compared with tp approach. therefore, the investigators performed randomized control trial to compare the outcomes of the two approaches (tp-lpn or rpn vs rp-lpn or rpn).

partial nephrectomy is the standard treatment for small renal masses. the evolution of minimally invasive partial nephrectomy led to widespread utilization of laparoscopic (lpn) and robotic partial nephrectomy (rpn). both lpn and rpn can be performed through transperitoneal (tp) or retroperitoneal (rp) approach. rp approach is less utilized than tp approach because of technical difficulties when using rigid laparoscopic instruments in the small space of retroperitoneum cavity. however, with advanced surgical skills and thoughtful patient selection, rp approach may be associated with shorter ot, less ebl, shorter los compared with tp approach. therefore, the investigators performed randomized control trial to compare the outcomes of the two approaches (tp-lpn or rpn vs rp-lpn or rpn). the purpose of this study to compare the treatment outcomes of the transperitoneal and retroperitoneal approach during lpn or rpn in treatment of small renal masses. inclusion criteria during the study period, a small renal mass (less than 4cm, t1a stage) patients are going to underwent lpn or rpn. exclusion criteria 1. patients who underwent radical nephrectomy 2. patients with bilateral renal masses 3. patients with a solitary kidney 4. patients reject a written informed consent 5. pregnancy the number of target subjects more than 106 patients who meet the inclusion criteria

Eligibility criteria:
inclusion criteria: * patients are going to undergo lpn or rpn with renal mass =\<4cm exclusion criteria: * bilateral renal masses solitary kidney previous underwent nephrectomy refuse to be enrolled the study pregnancy

Keywords: robot; laparoscopic partial nephrectomy transperitoneal retroperitoneal laparoscopic surgery surgical procedures, robotic nephrectomy
azilsaltan tablets (azilva tablets) special drug use surveillance "hypertension complicated by diabetes "

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the efficacy of azilsartan tablets (azilva tablets) in patients with hypertension complicated by diabetes mellitus whose blood pressure cannot be sufficiently reduced by monotherapy with angiotensin ii receptor blockers (arbs) other than azilsartan, in routine clinical practice

this study was designed to evaluate the efficacy of azilsartan tablets (azilva tablets) in patients with hypertension complicated by diabetes mellitus whose blood pressure cannot be sufficiently reduced by monotherapy with arbs, other than azilsartan, in daily medical practice. patient enrollment will be started on april 1, 2014. the usual dosage for adults is 20 mg of azilsartan administered orally once daily. the dose can be adjusted according to the participant's age and condition. the maximum daily dose is 40 mg.

Eligibility criteria:
inclusion criteria: * patients with hypertension who meet all the following criteria will be enrolled: 1. patients who has complications of diabetes mellitus 2. patients who is on monotherapy with arbs (other than azilsartan) as antihypertensive treatment (patients who have continued monotherapy with the same arb product for at least 8 weeks at the time of step-1\* of participant enrollment and will continue such treatment until the first administration of azilsartan tablets) 3. patients who has a systolic blood pressure of ≥ 130 millimeter of mercury (mmhg) and/or diastolic blood pressure of 80 ≥ mmhg at the examination performed at the medical institution 4. patients who is an outpatient 5. patient who keeps a regular lifestyle and whose usual waking time is between 4 a.m. and 9:30 a.m. \*for this surveillance, participant enrollment will be performed in two divided steps: step-1 (at hospital visit before prescription of azilsartan tablets) and step-2 (at the time of prescription of azilsartan tablets). exclusion criteria: * patients with contraindications to azilsartan

Keywords: pharmacological therapy
study of nivolumab (bms-936558) plus ipilimumab compared with ipilimumab alone in the treatment of previously untreated, unresectable, or metastatic melanoma

Conditions: Unresectable Melanoma; Metastatic Melanoma

Summary: the primary purpose of this study is to compare the objective response rate, as determined by investigators, of nivolumab combined with ipilimumab versus ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com key inclusion criteria: * eastern cooperative oncology group performance status of 0 or 1 * histologically confirmed unresectable stage iii or stage iv melanoma * no prior systemic anticancer therapy for unresectable or metastatic melanoma. note that prior adjuvant or neoadjuvant melanoma therapy is permitted if it was completed at least 6 weeks prior to date of first dose, and all related adverse events have either returned to baseline or stabilized * tumor tissue obtained in the metastatic setting or from an unresectable site must be provided for biomarker analyses and sent to the central laboratory. biopsy should be excisional, incisional punch, or core needle. fine needle aspirates or other cytology samples are insufficient * known braf v600 mutation status as determined by an fda-approved test. patients with either v600 wild-type or v600 mutation-positive melanoma are eligible. key exclusion criteria: * active brain metastases or leptomeningeal metastases. patients with treated brain metastases are eligible if there is no evidence of progression on magnetic resonance imaging scan for at least 8 weeks after completion of treatment and within 28 days prior to first dose of study drug administration. there must also be no requirement for high doses of systemic corticosteroids that could result in immunosuppression (\>10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration * ocular melanoma * patients with active, known, or suspected autoimmune disease. those with vitiligo, type i diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
neurofeedback improves cognitive performance and eeg activity in elderly with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this is a non-pharmacological pilot study showing the improvement of a smr/theta neurofeedback training program on cognitive performance and eeg activity in elderly with mild cognitive impairment.

neurofeedback training (nf) as self-regulation method of brain activity, may be beneficial in elderly with mild cognitive impairment. in this pilot study, the investigators studied whether a sensorimotor(smr)/theta nf training could improve cognitive performance and brain electrical activity in a sample group of elderly patients with mild cognitive impairment. twenty participants performed an electroencephalography recording, a battery of neuropsychological tests before the neurofeedback training program (t0), following the neurofeedback training program (t1) and 1-month follow-up (t2).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment * education level of 9 years of studies minimum * righthandedness * subjective memory complaint confirmed by an informant * a mini mental status examination score \>20. * preserve activity of daily living and absence of dementia. exclusion criteria: * elderly persons who were under guardianship * resident in nursing facilities * neurological disease, psychiatric disease * and involved in another cogniitve intervention.

Keywords: neurofeedback electroencephalography mci alzheimer
internal photobiomodulation for management of temporomandibular joint internal derangement

Conditions: Temporomandibular Joint Disorders

Summary: aim of the study was to compare the efficacy of internal versus external photobiomodulation (pbm) in the management of patients with tmj internal derangements (tmj-id).


Eligibility criteria:
inclusion criteria: * painful click at temporomandibular joint (tmj) area. * pain at the lateral pterygoid muscle. * presence of full or nearly full complement of natural teeth with acceptable occlusion exclusion criteria: * patients who have radiographic evidence of degenerative conditions of tmj. * patients under current dental or physical therapy that could affect tmd. * history of recent trauma. * the presence of systemic diseases (i.e. rheumatoid arthritis, osteoarthritis). * pregnant and lactating females. * presence of open bite.